News | November 05, 2008

Lantheus Welcomes New Consensus Statement on Echo Contrast Use

November 6, 2008 - Lantheus Medical Imaging Inc. welcomes the “Consensus Statement on the Clinical Applications of Ultrasound Contrast” released by the American Society of Echocardiography (ASE) published in the November issue of the Journal of the American Society of Echocardiography.

Developed by members of the U.S. echocardiography community, ASE’s consensus statement outlines when and how ultrasound contrast agents are to be used appropriately and efficiently to enhance the diagnostic capability of echocardiography.

“We applaud the American Society of Echocardiography for its leadership in addressing the effective use of contrast ultrasound by authoring the Contrast Consensus Statement guidance document for the echocardiography community. This important consensus statement speaks to the clinical relevance of contrast and guides clinicians towards a team-approach to care for effective contrast use,” said Don Kiepert, president and CEO, Lantheus Medical Imaging. “The release of this consensus statement serves to validate the clinical need of ultrasound contrast use in echocardiography and reinforces the important role contrast plays in clinical diagnosis, patient management and clinical research.”

ASE’s statement substantiates the established use of ultrasound contrast agents in diagnostic cardiovascular imaging in echocardiography and discusses the important role physicians, sonographers and nurses play in efficiently integrating the use of contrast agents into the echocardiography laboratory. Additionally, the document highlights the role of echocardiography contrast imaging agents in improving cardiac structural definition and outlines the clinical situations when non-enhanced imaging does not yield diagnostic information. Lantheus’ echocardiography contrast agent, DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension, is specifically indicated for the use of patients with suboptimal echocardiograms to opacify the left ventricular chamber. Although the consensus statement also discusses, among other things, the use of contrast agents in stress echocardiography, the safety and efficacy of DEFINITY with exercise stress or pharmacologic stress testing have not been established, the company said.

The recommendations are based on a critical review of the existing medical literature, including prospective clinical trials, and when no significant study data were available, expert consensus opinion. The statement also thoroughly reviewed the recent labeling changes by the FDA regarding ultrasound contrast agent use and safety information.

In May 2008, Lantheus announced the initiation of CaRES (Contrast Echocardiography REgistry for Safety Surveillance), a multi-center Phase IV observational study that will further evaluate the safety profile of DEFINITY in patients with suboptimal echocardiograms and provide safety information on the use of ultrasound contrast agents in routine clinical practice. The open-label, non-randomized registry is being conducted in more than 10 clinical sites in the U.S. and include at least 1,600 patients. The study will gather data on patient characteristics and demographics, indication for DEFINITY’s use, results of safety monitoring of patients during and after DEFINITY administration, and the nature and frequency of any adverse events that may occur.

The FDA issued a black box warning for echo contrast agents last fall, but this summer downgraded the level of warning. The FDA reports there have been some rare but serious cardiopulmonary reactions, including fatalities, during or following perflutren-containing microsphere administration. The FDA now requires clinicians to assess all patients for the presence of any condition that precludes echo contrast agent administration. In patients with pulmonary hypertension or unstable cardiopulmonary conditions, clinicians are supposed to monitor vital sign measurements, electrocardiography and cutaneous oxygen saturation during and for at least 30 minutes after administration.

Lantheus said DEFINITY should not be administered to patients with known or suspected cardiac shunts (right-to-left, bi-directional or transient right-to-left), or hypersensitivity to perflutren. It also should not be administered by intra-arterial injection.

For more information: www.lantheus.com

Related Content

Siemens Healthineers Showcases New In Vivo and In Vitro Cardiovascular Solutions at TCT 2018
News | Ultrasound Imaging | September 21, 2018
At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) conference, Sept. 21-25 in San Diego, Siemens Healthineers...
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cardiac Imaging | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Siemens Healthineers Announces First Installation of Acuson Sequoia Ultrasound
News | Ultrasound Imaging | September 20, 2018
September 20, 2018 — Siemens Healthineers announced the first global installation of its newest...
LVivo EF Cardiac Tool Now Available for GE Vscan Extend Handheld Mobile Ultrasound
Technology | Cardiovascular Ultrasound | September 19, 2018
DiA Imaging Analysis Ltd. (DiA), a provider of artificial intelligence (AI)-powered ultrasound analysis tools,...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Acuson Sequoia
News | Ultrasound Imaging | September 12, 2018
Siemens Healthineers announced the first global installation of its newest ultrasound system, the...
Mount Sinai Serves as Official Medical Services Provider for 2018 U.S. Open
News | Orthopedic Imaging | September 06, 2018
For the sixth consecutive year, Mount Sinai will serve as the official medical services provider for the 2018 U.S. Open...
Konica Minolta Provides Sonimage HS1 Ultrasound for AAPM&R Hands-on Learning Course
News | Ultrasound Imaging | September 05, 2018
Konica Minolta Healthcare Americas recently provided ultrasound systems for The American Academy for Physical Medicine...
Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.

News | Oncology Diagnostics | August 24, 2018
A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing...